{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:00:05Z","timestamp":1775041205583,"version":"3.50.1"},"reference-count":61,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848015011"],"award-info":[{"award-number":["848015011"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>For over more than a decade, low-dose amitriptyline and mirtazapine are prescribed off-label for insomnia. However, placebo-controlled evidence on these antidepressants for insomnia is still lacking. Therefore, the present trial aims to assess the effectiveness of low-dose amitriptyline (10\u201320\u2009mg\/day) and mirtazapine (7.5\u201315\u2009mg\/day) in patients with insomnia disorder with difficulty maintaining sleep or early-morning awakening problems in general practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The Drug REdiscovery: low-dose Amitriptyline and Mirtazapine for INsomnia disorder in General practice (DREAMING) study is a randomised, double-blind, placebo-controlled trial in about 50 general practices. Adults (18\u201385 years) with insomnia disorder (Diagnostic and Statistical Manual of Mental Disorders-5) who ask their general practitioner (GP) for sleep medication when non-pharmacological treatment is deemed not effective, are eligible. Exclusion criteria: isolated sleep initiation problem, contraindications for or drug\u2013drug interactions with either amitriptyline or mirtazapine. Participants (n=156) will be randomly assigned to three parallel treatment groups of 16-week treatment with either amitriptyline (one or two tablets of 10\u2009mg\/day) or mirtazapine (one or two tablets of 7.5\u2009mg\/day) or placebo (one or two tablets) alongside usual GP care. All participants start and end with single dose, but dose can be doubled following GP consultation in week 3. Questionnaire assessments will be conducted at baseline, week 6, 12, 20 and 52. The primary study outcome is self-reported insomnia severity at 6 weeks, measured with the Insomnia Severity Index (ISI) in an intention to treat analysis. Secondary outcomes include subjective sleep quality quantified by sleep indices, daytime functioning and symptoms, safety and treatment evaluation and other sleep care consumption.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The Medical Ethics Committee of the VU Medical Centre Amsterdam approved this trial. The results of this trial will be published in peer-reviewed scientific journals and presented at relevant academic conferences and to key stakeholders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>NTR7449.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2020-047142","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T08:12:57Z","timestamp":1644826377000},"page":"e047142","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of low-dose amitriptyline and mirtazapine for insomnia disorder: study protocol of a randomised, double-blind, placebo-controlled trial in general practice (the DREAMING study)"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-1981","authenticated-orcid":false,"given":"Mette H","family":"Bakker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline G","family":"Hugtenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke","family":"van Straten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4060-4354","authenticated-orcid":false,"given":"Henri\u00ebtte E","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Slottje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"2022021323315466000_11.9.e047142.1","doi-asserted-by":"publisher","DOI":"10.1053\/smrv.2002.0186"},{"key":"2022021323315466000_11.9.e047142.2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th Edn. Washington DC, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2022021323315466000_11.9.e047142.3","doi-asserted-by":"publisher","DOI":"10.1177\/2047487312460020"},{"key":"2022021323315466000_11.9.e047142.4","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m12020","article-title":"Insomnia and impaired quality of life in the United States","volume":"79","author":"Olfson","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"2022021323315466000_11.9.e047142.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2008.04.005"},{"key":"2022021323315466000_11.9.e047142.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.08.008"},{"key":"2022021323315466000_11.9.e047142.7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5664\/jcsm.27286","article-title":"Clinical guideline for the evaluation and management of chronic insomnia in adults","volume":"4","author":"Schutte-Rodin","year":"2008","journal-title":"J Clin Sleep Med"},{"key":"2022021323315466000_11.9.e047142.8","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2175"},{"key":"2022021323315466000_11.9.e047142.9","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.sleep.2017.03.017","article-title":"Australasian sleep association position statement regarding the use of psychological\/behavioral treatments in the management of insomnia in adults","volume":"36 Suppl 1","author":"Ree","year":"2017","journal-title":"Sleep Med"},{"key":"2022021323315466000_11.9.e047142.10","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12594"},{"key":"2022021323315466000_11.9.e047142.11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/NSS.S198812","article-title":"Impact of phenotypic heterogeneity of insomnia on the patients' response to cognitive-behavioral therapy for insomnia: current perspectives","volume":"11","author":"Galbiati","year":"2019","journal-title":"Nat Sci Sleep"},{"key":"2022021323315466000_11.9.e047142.12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jsmc.2019.01.006","article-title":"Cognitive behavioral therapies for insomnia and hypnotic medications: considerations and controversies","volume":"14","author":"Cheung","year":"2019","journal-title":"Sleep Med Clin"},{"key":"2022021323315466000_11.9.e047142.13","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2841"},{"key":"2022021323315466000_11.9.e047142.14","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000505600","article-title":"Nurse-guided internet-delivered cognitive behavioral therapy for insomnia in general practice: results from a pragmatic randomized clinical trial","volume":"89","author":"Van der Zweerde","year":"2020","journal-title":"Psychother Psychosom"},{"key":"2022021323315466000_11.9.e047142.15","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp14X677176"},{"key":"2022021323315466000_11.9.e047142.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2006.01.002"},{"key":"2022021323315466000_11.9.e047142.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38623.768588.47"},{"key":"2022021323315466000_11.9.e047142.18","article-title":"Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"2022021323315466000_11.9.e047142.19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/DHPS.S21079","article-title":"Prevalence and factors associated with off-label antidepressant prescriptions for insomnia","volume":"3","author":"Lai","year":"2011","journal-title":"Drug Healthc Patient Saf"},{"key":"2022021323315466000_11.9.e047142.20","first-page":"42","article-title":"Therapeutic options in the treatment of insomnia","volume":"66","author":"Erman","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"2022021323315466000_11.9.e047142.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2008.08.001"},{"key":"2022021323315466000_11.9.e047142.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2869.2009.00769.x"},{"key":"2022021323315466000_11.9.e047142.23","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-012-0003-6"},{"key":"2022021323315466000_11.9.e047142.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2012.08.001"},{"key":"2022021323315466000_11.9.e047142.25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/JCP.0000000000000338","article-title":"Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in the Netherlands","volume":"35","author":"Kamphuis","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"2022021323315466000_11.9.e047142.26","first-page":"Cd010753","article-title":"Antidepressants for insomnia in adults","volume":"5","author":"Everitt","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2022021323315466000_11.9.e047142.27","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/sleep\/33.11.1553","article-title":"Efficacy and safety of doxepin 1 Mg and 3 Mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia","volume":"33","author":"Krystal","year":"2010","journal-title":"Sleep"},{"key":"2022021323315466000_11.9.e047142.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2011.09.006"},{"key":"2022021323315466000_11.9.e047142.29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n1005"},{"key":"2022021323315466000_11.9.e047142.30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17010050","article-title":"Pharmacotherapy treatment options for insomnia: a primer for clinicians","volume":"17","author":"Asnis","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2022021323315466000_11.9.e047142.31","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.sleep.2015.03.005","article-title":"Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial","volume":"16","author":"Ivgy-May","year":"2015","journal-title":"Sleep Med"},{"key":"2022021323315466000_11.9.e047142.32","unstructured":"International Conference on Harmonisation Good Clinical Practice . ICH harmonised guideline. In: Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R1. International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2016."},{"key":"2022021323315466000_11.9.e047142.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"2022021323315466000_11.9.e047142.34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2390"},{"key":"2022021323315466000_11.9.e047142.35","first-page":"352","article-title":"NHG-standaard slaapproblemen en slaapmiddelen (tweede herziening)","volume":"57","year":"2014","journal-title":"Huisarts Wet"},{"key":"2022021323315466000_11.9.e047142.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-016-0783-z","article-title":"Cost-effectiveness of i-sleep, a guided online CBT intervention, for patients with insomnia in general practice: protocol of a pragmatic randomized controlled trial","volume":"16","author":"van der Zweerde","year":"2016","journal-title":"BMC Psychiatry"},{"key":"2022021323315466000_11.9.e047142.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(00)00065-4"},{"key":"2022021323315466000_11.9.e047142.38","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/34.5.601"},{"key":"2022021323315466000_11.9.e047142.39","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2013.06.130064"},{"key":"2022021323315466000_11.9.e047142.40","doi-asserted-by":"publisher","DOI":"10.1080\/15402002.2011.606766"},{"key":"2022021323315466000_11.9.e047142.41","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/sleep\/29.9.1155","article-title":"Recommendations for a standard research assessment of insomnia","volume":"29","author":"Buysse","year":"2006","journal-title":"Sleep"},{"key":"2022021323315466000_11.9.e047142.42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.sleep.2012.10.023","article-title":"The Glasgow sleep impact index (GSII): a novel patient-centred measure for assessing sleep-related quality of life impairment in insomnia disorder","volume":"14","author":"Kyle","year":"2013","journal-title":"Sleep Med"},{"key":"2022021323315466000_11.9.e047142.43","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R725"},{"key":"2022021323315466000_11.9.e047142.44","first-page":"2158","article-title":"Low dose amitriptyline in ankylosing spondylitis: a short term, double blind, placebo controlled study","volume":"24","author":"Koh","year":"1997","journal-title":"J Rheumatol"},{"key":"2022021323315466000_11.9.e047142.45","first-page":"231","article-title":"Subjective hypnotic efficacy of trazodone and mirtazapine in patients with chronic insomnia: a retrospective, comparative study","volume":"153","author":"Savarese","year":"2015","journal-title":"Arch Ital Biol"},{"key":"2022021323315466000_11.9.e047142.46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5665\/sleep\/32.3.351","article-title":"Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia","volume":"32","author":"Mayer","year":"2009","journal-title":"Sleep"},{"key":"2022021323315466000_11.9.e047142.47","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/sleep\/30.8.959","article-title":"Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations","volume":"30","author":"Walsh","year":"2007","journal-title":"Sleep"},{"key":"2022021323315466000_11.9.e047142.48","unstructured":"Cohen J . Statistical power analysis for the behavioral sciences. 2 ed. New York: Lawrence Erlbaum Associates, 1988."},{"key":"2022021323315466000_11.9.e047142.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.11.010"},{"key":"2022021323315466000_11.9.e047142.50","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"2022021323315466000_11.9.e047142.51","doi-asserted-by":"publisher","DOI":"10.1179\/jmt.2009.17.3.163"},{"key":"2022021323315466000_11.9.e047142.52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5665\/sleep.1642","article-title":"The consensus sleep diary: standardizing prospective sleep self-monitoring","volume":"35","author":"Carney","year":"2012","journal-title":"Sleep"},{"key":"2022021323315466000_11.9.e047142.53","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.180.5.461"},{"key":"2022021323315466000_11.9.e047142.54","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3999(94)00125-O"},{"key":"2022021323315466000_11.9.e047142.55","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5664\/jcsm.27030","article-title":"The Flinders fatigue scale: preliminary psychometric properties and clinical sensitivity of a new scale for measuring daytime fatigue associated with insomnia","volume":"3","author":"Gradisar","year":"2007","journal-title":"J Clin Sleep Med"},{"key":"2022021323315466000_11.9.e047142.56","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-5-46"},{"key":"2022021323315466000_11.9.e047142.57","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291796004382"},{"key":"2022021323315466000_11.9.e047142.58","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.061960"},{"key":"2022021323315466000_11.9.e047142.59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-147"},{"key":"2022021323315466000_11.9.e047142.60","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00126-7"},{"key":"2022021323315466000_11.9.e047142.61","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0921-x"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-047142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T08:13:18Z","timestamp":1644826398000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-047142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,2]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bmjopen-2020-047142"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-047142","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}